SERUM FREE MEDIA FOR THE GROWTH OF INSECT CELLS AND EXPRESSION OF PRODUCTS THEREBY

Abstract: Serum free media which support the growth of insect cells and the production thereby of recombinant proteins and viral products are herein disclosed. The serum free media can support insect cell growth at large scale under agitated and/or sparged, preferably well-aerated conditions. The serum free medium disclosed support insect cell growth to cell densities comparable to serum-containing culture and the production of viral and recombinant products to levels equivalent to those found in serum containing culture.

Description: SERUM FREE MEDIA FOR THE GROWTH OF INSECT CELLS AND EXPRESSION OF PRODUCTS THEREBY This invention 1s 1n the field of fermentation and insect cell culture. More particularly, the invention concerns Improved media for the cultivation and reproduction of Insect cells. Further, this Invention concerns serum free media which support the large scale growth of Insect cells. Still further, this Invention concerns the expression at high levels of recombinant or viral products by Insect cells grown in said serum free media that are infected respectively either by a recombinant baculovirus or by a wild-type virus. Insect cells have been successfully used to replicate bacuioviruses to promote expression of foreign genes carried by bacuioviruses. [Smith et al., PNAS (USA), 82:8404-8408 (Dec, 1985) wherein Spodoptera frugiperda cells Infected with recombinant Autographa californica nuclear polyhedrosis viruses (AcNPV) carrying cDNA coding for human IL-2 are reported to produce high levels of IL- 2; see also, Smith et al., European Patent Application Publication No. 127,839 (published Dec. 12, 1984), wherein methods for producing recombinant bacuioviruses capable of expressing selected genes in host insect cells are disclosed; and Jeang et al., J. Virol., 61 (3):708- 713 (March 1987), wherein the production of functional human T-cell leukemia virus type I (HTLY-I) p40 x protein by S. fruglperda (Sf9) cells Infected with a recombinant AcNPV virus Is reported.] Insect cells have been cultured for the production of Insect viruses as biological Insecticides. [Vaughn et al., In Vitro, 13:213- 217 (1977); Lynn et al., J. Invert. Pathol., 32 ^ :1-5 (1978)]. Such viruses Include, for example, bacuioviruses and non-baculovlruses such as Infectious flacheriae virus ( IFV ) and cytopl as ic polyhedrosis virus (CPV ). Exemplary are certain bacuioviruses, for example, nucleopolyhedrosls viruses (NPV ) and granulosls viruses (GV), which are highly virulent for pest Insects; some of the most promising have been commercially developed as biological pesticides pathogenic for agriculturally important Insects. [Surges (ed. ), Microblal Control of Pests and Plant Diseases 1970-1980 (London, 1981); MUtenburger et al . , Bioinsecticides II : Baculoviridae. Adv. Blotechnol . Processes, 291 (1984 ); for a discussion of such NPV and GV products as biological pesticides, see Shleh et al ., "Production and Efficiency of Bacuioviruses," Biotechnology and BioenglneeHng Vol . XXII , 1357 ( 1980); see also Huber, "Use of Bacuioviruses 1n Pest Management Programs, " _In_ Granados et al . , (eds. ), The Biology of Bacuioviruses : Vol . II Practical Appl ications for Insect Control , pp. 181-202 (1986 ).] - ■•■■ ' Bacuioviruses are very stable and are able to persist for longer times in the environment than other animal viruses. This unusual biological stability is the result of a unique association of the infectious virus particles and a viral occlusion which is a crystalline assembly of a viral encoded structural protein called polyhedrin. Late in viral replication, baculovirus particles become embedded in a protein occlusion composed of the polyhedrin protein. Insects acquire a baculovirus disease by ingesting these occluded virus (OV) contaminating their food supply. The polyhedrin matrix protects the virus particles outside of the insect and also during their passage through the foregut of the Insect. In the . insect midgut, the alkaline pH activates the dissolution of the polyhedrin crystalline matrix resulting In the release of many viruses. The virus becomes absorbed by the midgut epithelial cells Initiating the infection process. There Is a second infectious foπa of nuclear polyhedrosis viruses (NPVs), known as the extracellular or noπoccluded virus (NOV) form, which 1s generated by toe budding of viral nucleocapsids through the plasma membrane of the Infected cells. NOYs are responsible for spreading the secondary infection via the he olymph of the Insect. Traditionally, production of bacuioviruses was achieved using insect larvae; however, large sale production by such means 1s not attractive. Insect cell culture 1s much more practical. [Vaughn, Adv. Cell. Cult., 1:281-295 (1981); Stockton et al., ln_ Burges (ed.), supra, at 313-328.] Batchwise and semicontinuous production of Spodoptera fruglperda and Trichoplusia n1 cells that allow the replication of Autographa californlca nuclear polyhedrosis virus have been reported. [Vaughn, J. Invert. Path., 28:233-237 (1976); Hink, _l£. Kurstak (ed.), Microbial Viral Pesticides at 493-506 (1982).] To obtain the maximum yield of Insect cells 1n culture with minimum population doubling time, the cells must be provided with ideal nutritional, biological, and biophysical requirements for growth. One of the most Important variables Is the composition of the Insect cell culture media. The basis of a commonly employed medium for lepidopteran cells was a medium developed by Wyatt, J. Gen. Physio!., _39_:841 (1956) and modified by Grace, Nature (London), 195:788 (1962). That medium resembles hemolymph and consists mainly of chemically pure ami no adds, vitamins, organic acids and Inorganic salts, and originally was supplemented with Insect hemolymph. Later the hemolymph from this formulation was replaced by fetal bovine serum, bovine serum albumin, and whole-egg ultrafiltrate. [Weiss et al., Chapter 3, page 68, In Granados et al . (eds), The Biology of Bacuioviruses (VόT II) 1986; citations omi ted. J The cultivation of insect cells Jhτ_ vitro at large scale, infecting the cells with either recombinant or non-recombinant viruses, and work-up of the recombinant product or the virus material depends on the availability of a suitable culture medium. As Indicated above, conventional culture media contain, 1n addition to Inorganic salts, vitamins, aπrfno acids, sugars, and a number of other organic compounds important for cell physiology, about 2-25% by weight per volume of animal serin and/or animal serum albumin. Animal serum is a limiting factor due to Its high price and relatively scarce availability, and further, because of the complications it creates for product purification. Production of insect cells on a scale required for either the Industrial manufacture of Insect pathogenic viruses or of recombinant products necessitates the replacement of animal serum by a cheaper component available in sufficient quantities. There have been a number of studies done to develop serum- free media for the cultivation of Insect cells, many of which are 1n the context of producing NPV and GV as biological pesticides and which Include the following: Goodwin et al., in Kurstak et al. (eds.) Invertebrate Systems In Vitro, Chapter 45:493-509 (1980); Goodwin, Jn. Vitro, 12:303-304 (1976); Hink et al., In Vitro, 23:177 (1977); Roder, U.S. Patent No. 4,454,227; Weiss et al., In Vitro, 20:271 (1984); Gardiner et al., J. Invert. Path., 5_:363-370 (1970); Wilkle et al., Develop. Biol. Standard., 4629-37 (1980); and Vail et al., J. Invert. Path., 28263-267 (1976). Table 1 lists a number of the media wherein serum was replaced by protein hydrolyzates and crude and defined lipids. Such serum- free media were reported to support the production of baculovirus in insect (Lepidopteran) cells a though some of the media did not produce viable occluded virus. TABLE 1 Lepidopteran Serum-Free Culture Report Cell Line Medium Hink et al . In Vitro, Trichoplusia ni Defined medium 13:177 (19771 + Bactotr ptose Goodwin et al., In Vitro, Porthetri dispar Defined medium 12:303 (1976) " ~ + Hver digest, peptic peptone, yeast extract, Lactalbumin Hydro! y sate Roder, Naturwissenschaften, Spodoptera fruglperda Defined medium + 69:92 (1982) peptones, egg yolk Weiss et al., In Vitro, Heliothls zea RIL-2B medium + 20:271 (1984) sterols, fatty acids Goodwin et al., Invert. Lymantria dispar Defined medium + Systems, Chap 4574 " 93 peptones, glutamine, (1980) glycerol , α-glycero- phosphate, oleate, Tweeπ 80, cholesterol , a- Tocopherol In regard to such serum free media, Weiss et al. points out 1n The Biology of Bacuioviruses, (CRC Press 1986) supra, at page 68 that: Research findings on the role and utilization of amlno acids, minerals, hormones, ltogens, carbohydrates, organic acids, fatty acids, sugars, lipids, and monovalent and divalent cations 1n cultured insect cells have led to some experimental application of serum-free media for Insect cells. However, to date these serum-free media are not completely satisfactory for viral replication, which may be attributed to the absence of undefined proteins normally in serum supplements. [Citations omitted.] In the context of culturing insect cells for the production of recombinant proteins via a baculovirus expression vector system (BEVS), Miller et al . [In: Setlow et al . (eds.), Genetic Engineering Principles and Methods (Vol 8): "An Insect Baculovirus Host-Vector System for High-Level Expression of Foreign Genes," pp. 277-298 (1986)] states at page 291: "Typically 10% fetal calf serum is present throughout cell and viral growth. The protein contributed by the serum can be a problem for purification and perhaps expression 1f it contains certain antagonistic activities. While the literature contains reports of insect cells growing in serum-free media, such media do not readily support viral growth." Miller et al . then notes that U.S. Patent No. 4,454,227 to Roder wherein an egg yolk emulsion is used as a serum replacement is an "Interesting exception" but that 1t "1s not clear that 1t_ eases purification problems. As a short term solution, we have observed that, once Infected In 10% serum-containing media, cells can be transferred to a serum-free media and expression will occur largely unabated." However, such a transfer from serum- containing medium to a serum free medium, as suggested by Miller et al., 1s not a practical solution for large scale Industrial production. Summers et al . in "A Manual of Methods for Baculovirus Vectors and Insect Cell Culture Procedures" Texas Agricultural Experiment Bulletin No. 1555 (Texas A 4 M University; May 1987) recommends, at pages 32-33, the use of "Grace's Antheraea medium (a relatively simple mixture of salts, carbohydrates and amino acids) ...used for short term incubations of cells (rinsing monolayers, seeding cells, transfection, etc.)" and "TNM-FH, a more complete medium suitable for routine growth of cells 1n onolayer or suspension,... prepared from Grace's by toe addition of 3.3 g/Hter Yeastolate and 3.3 g/liter Lactalbumin Hydrolysate (both available from Difco)." Summers et al . goes on to state at page 33 that for "complete growth medium, add 10% fetal bovine serum (sterile, heat inactivated", and under the Methods section at pages 9 and 11, Summers et al. directs that "TNM-FH media + 10% FBS + antibiotics" be used. At page 10, Summers et al. states: "It is desirable to seed cells in serum-free medium to promote rapid and firm attachment for plaque assays, infections, etc. However, cells may begin to show signs of stress 1f they are left without serum for more than 2 hours." Most culture media for the growth of insect cells contain peptones and serum and are conventionally used to grow Insect cells under poorly aerated conditions which restrict the cells' growth and expression of recombinant proteins and viable viral particles. Although serum-free media have been developed that support insect cell growth, none of such media have been shown to support production of levels of recombinant proteins from insect cells grown in such serum- free media and Infected with a recombinant baculovirus, comparable to levels achieved from Insect cells so Infected and grown in approximately 10% serum-containing media. Further, as Indicated above, none have been shown to support viral repHsation 1n insect cells satisfactorily. Attempts to include lipid nutrients 1n Insect culture media have often resulted 1n the presence of large Insoluble lipid particles not easily available to cells. This invention solves that problem. The research described herein indicates that some of the peptones and other ingredients Included In published Insect culture media, both serum and non-serum containing, are growth Inhibitory or unnecessary. Further, toe research indicates that high molecular weight components of toe peptone fractions may interfere with the purification of the recombinant or viral products produced by the cultured Insect cells; this Invention provides a means to remove such components. Further^ of great value to toe art would be a single serum- free, low or no protein medium for the growth of insect cells and production of recombinant proteins or viral products thereby respectively either via a baculovirus expression vector system (BEYS) or by Infection with a wild-type virus. On a small scale, Insect cells can be grown in a serum-containing relatively high protein medium, and can then be separated from such growth medium and resuspended In a serum-free production medium for Infection and expression of products. Such separation and resuspension processes are not desirable for large scale culture because of the complexity of toe equipment and operations required for such procedures. There is a need 1n the art for a single serum-free and low or no protein growth and production medium which would simplify fermentation operations, reduce the cost of large scale insect cell culture, and aid in the purification of the recombinant and viral products. This Invention meets that need. A reason that poorly aerated conditions have been conventionally used In insect cell culture 1s because of "the fragility of Insect cells". [Weiss et al., The Biology of Bacuioviruses, Vol. II (Chapter 3) at page 80 (CRC Press 1986); Weiss et al., In Vitro, 16:222 (1980).] "Two problems appear to have delayed toe full utilization of suspension systems for toe large volume culture of Insect cells: toe fragility of insect cells, and second, the high oxygen demand, particularly for v1rus-1nfected cells." [Weiss et al., CRC Press, supra, p. 80; citations omitted.] Tramper et al., Enzyme Microb. Techno!., 8_:33-36 (January 1986) notes at p. 33: "A major problem encountered 1n scaling up [insect] cell . . culture systems is toe shear sensitivity of these cell s due to their size (20 m range) and lack of cell wall . The shear sensitivity may hamper the supply of sufficient oxygen in a conventional manner (e.g. , by sparging)." Tramper et al . further states at pages 35-36 : The mechanical strength of insect cell s in cul ture 1s small .... This has definite consequences for toe scale up of Insect cell cultures. Larger volumes of Insect cell cultures require more efficient oxygen transfer to the solution than can be achieved by flushing air/oxygen over the liquid surface. However, dispersion of gas by means of stirring and sparging air through toe cell suspension to provide sufficient oxygen probably resul ts 1n a larger decay rate than growth rate of toe cell s. The Instant Invention meets toe need of providing a medium in which insect cells can grow not only under toe poorly aerated conditions of conventional cul ture, but in well -aerated conditions wherein insect cells can grow to high cell density with high viabil ity and produce level s of recombinant products, when Infected wi th recombinant bacuioviruses, or of other viral products, when infected with wild-type viruses, comparable to l evel s achieved in serum- containing media. The present invention provides ror serum-free low or preferably no protein media for the large scale growth of insect cell s to high cell density with high viabil ity. The media of this Invention support insect cell growth to densities equivalent to those found in serum-containing media that have much higher protein content. Further, when insect cells are grown in toe media of this Invention, toe expression of recombinant products thereby and the production of other viral products, such as, NPV and GV, are equivalent to the expression and production of Insect cell s grown in serum-containing media. Further, this invention provides, for serum-free media that support both toe growth of insect cells as well as the production of recombinant proteins and other viral products, and is further compatible with toe purification of such recombinant proteins and viral products. _ _ Further, another aspect of this invention is an optional method of removing by ultrafil tratlon, high molecul ar weight components, residual proteases and endo toxins from the peptone fraction that had not been removed during its manufacture and which might interfere with purification of viral and recombinant products of the Insect cells. Therefore, another aspect of this Invention 1s serum-free media for insect cell culture which are substantially free of high molecular weight components, residual proteases and endotoxins. Al so, this Invention provides a lipid component In the form of a m1croemul s1on In the serum-free media. Such l ipid component comprises a lipid/organlc solvent solution containing a small amount of an emul si fier, or of a combination of emul sifiers. Preferred emul sifiers Include the * combination of a phosphol ipid, such as, lecithin, or more preferably a non-toxic, non-1onic polymeric detergent, such as, polysorbate 80, and a second emul sifier, preferably, a non-ionic polymeric detergent, more preferably, a Pluronic polyol , still more preferably Pluronic F68 or F88. Further, the serum-free media of this invention optionally comprise a non- toxic protective agent that prevents cel l damage and death caused by shear stress 1n agitated and/or sparged cul tures. Preferred non-tox1c protective agents of this invention are non-toxic water soluble polymers, more preferably non-toxic, non-ionic polymeric detergents, Pluronic polyol s, such as Pluronic F68 or Pluronic F88, still more preferably Pl uronic F68. Figure 1 Illustrates the time course for toe production of rCSF-1 by Sf9 Insect cel l s infected with recombinant baculovirus AcM6. The upper panel Indicates toe concentration of rCSF-1 as determined by RIA at 0-4 days post-1 nfecti on. The middle panel Indicates the viabil ity of toe Insect cell s as determined by counting cells using Trypan blue exclusion method over the same time period. The lower panel is a Western blot analysis of rCSF-1 produced. The serum- free, low protein or preferably no protein media of this Invention are designed for the growth of insect cell s at l arge scale. The media of this invention provide a good nutri tional environment for toe gre*th of Insect cells in agitated and/or sparged, and preferably well-aerated conditions. Insect cell s have a "high oxygen demand, particularly for virus-infected cell s." [Weiss et al . , CRC Press, supra, p. 80.] Therefore, media of this invention have also been designed to enhance cell growth and production of viral and recombinant products from Insect cell s and to protect the cell s from damage or deato under well -aerated conditions which are more physically demanding than static cul tures or other conventional cul tures which are less well -aerated. "Wel l -aerated" herein refers to non-oxygen l imi ted conditions as those created by agitation, for example, in spinner or rol ler bottles and stirred or shake flasks, or by sparging, for example, in airl ift ferme tors. The term "protein" is herein defined to excl ude the term "peptones." The serum-free media of this invention preferably contain very low concentrations of protein, that is, less than about 1000 υg/ml , more preferably less than about 50 ug/ml , and still more preferably less than about 5 pg/ml , and even more preferably no protein. The term "peptone" 1s defined herein as a mixture of cleavage products produced by the partial hydrolysis of a native protein either by an add or an enzyme. Peptones used 1n the serum- free media of this invention are preferably of a molecul ar weight less than about 15,000, and more preferably of a molecular weight less than about 10,000. In one aspect of this invention, the serum- free media of this invention include: (a) a basal medium; (b) a Hpid component; and (c) a peptone component. A "basal medium" 1s herein defined as a nutrient mixture of Inorganic salts, sugars, amlno adds, optionally also containing vitamins, organic adds and/or buffers. Basal media together with supplements provide toe nutrients necessary to support cell life, growth and reproduction. The preferred basal media used as the starting point for the preparation of the serum free media of toe present Invention contain neither serum, nor proteins, nor preferably any peptones. The choice of basal medium for the preparation of the media of this Invention is not critical. The basal medium can also be considered optional in the sense that appropriate peptone and lipid components can be selected which provide such necessary nutrients as ami no acids and vitamins required to support cell life, growth and reproduction. There are a wide variety of commercially available basal media that can be used in the media of this Invention. Such commercially available basal medium Include, for example, TCIO without tryptose broth [commercially available from Microbiological Associates; see Gardiner et al., J. Invert. Pathol., 5_:363 (1975)], Grace's Antheraea medium [Yaughn et al., TCA Manual, jjjl) (1976); Yunker et al., Science, 11:1565-1566 (1967)], Medium M20 of Mark's [Vaughn et al., TCA Manual, _3_ (D [1976); Marks, _I>1 κ ™se et al. (eds.), Tissue Culture Methods and Applications, pp. 153-156 (1973)], Goodwin's IPL-52 Medium [Goodwin, In Vitro, I :369 -38 (1975)], Goodwin's IPL Medium [Goodwin et al., Jϋ Kurstak et al . (eds.), Invertebrate Systems In Vitro (1980)], Goodwin's IPL-76 Peptone Medium [Goodwin et al., j j d^; Goodwin et al., In Vi ro, , 14485-494 (1978)], Hink's TMH FH Medium (Revised) [H1nk, Nature (London), 226:466-467 (1970)], Medium S-301 of Hansen [Hansen, JjL Maramorosch (ed.), Invertebrate Tissue Culture Research Applications, pp. 75-99 (1976); Vaughn et al., TCA Manual, 3(1) (1976)], and IPL-41 Medium [Weiss et al., In Vitro, YJ_ (6):495-502 (1981)], wherein IPL-41 is a preferred basal medium. As indicated, IPL-41 Is a preferred basal medium for the preparation of toe media for tois Invention. IPL-41 basal medium Is commercially available from a number of vendors and is described in Weiss et al., In Vitro, ^Z. (6):495-502 (June 1981) and 1n Weiss et al., CRC Press, supra, pp. 70-72 (1986). Table 1 of Weiss et al . (In Vitro) at page 496, and Table 3 of Weiss et al. CRC Press, at pages 71-72 outline all the components of IPL-41 and provide toeir proportions in mg/1; said tables are herein Incorporated by reference. At page 497 of Weiss et al . (In Vitro), toe preparation of the complete medium IPL-41 is described wherein tryptose phosphate broth (TPB) and fetal bovine serum (FBS) are added. The IPL-41 basal medium employed 1n preparing the serum- free media of this Invention does not contain tryptose phosphate broth (TPB) or fetal bovine serum (FBS). The serum- free media of this invention can further comprise a protective agent. Such a protective agent is a preferred component of the media of. tois invention, especially under well-aerated culture conditions. Therefore, the serum-free media of this Invention include: (a) a basal medium; (b) a lipid component; (c) a peptone component; and (d) a protective agent. A protective agent Is necessary to prevent cell damage and deato under well -aerated conditions as found in well agitated and sparged cultures. The protective agent prevents a d1s1ntegrati on/clumping phenomenon of insect cells grown in shake flasks and adherence of the cells to toe vessel walls. Further, the protective agent reduces the amount of cellular debris In shake flask cultures indicating that cell lysis is reduced by toe presence of the protectant. The protective agent further preferably acts as an anti- foaming agent preventing the loss of cells from toe free suspension Into a foam layer, and can act as a bubble surface tension reducing agent and/or as a cell surface stabilizing agent and/or as a viscosifying agent. Protective agents are herein defined as non-toxic, water soluble compounds that functionally act to protect Insect cells from damage and death In agitated and sparged Insect cell culture. The protective agents of this invention are preferably non-toxic, water soluble polymers. A protective agent candidate can be selected by first confirming that 1t 1s not toxic to the Insect cells to be cultured by methods known to those skilled in toe art of Insect cell culture, for example, by adding it to a suspension or onolayer of the Insect cells of choice for cultivation and comparing the growth of the culture to a control. Then, the non-toxic protective agent candidates can be tested for protective ability by adding the candidate agent to an agitated or sparged culture of the insect cells of choice at small scale and observing viability and growth rate after an appropriate period and comparing the viability and growth rate of the cells of said culture to the viability and growth rate of the cells in a control culture. The protective agents in the media of this invention are preferably cell surface stabilizing agents and/or viscosifying agents and/or bubble surface tension reducing agents. Examples of preferred protective agents are hydroxyethyl starch, methyl cellulose, carboxymethyl cellulose (as, sodium carboxymethyl cellulose), dextran sulfate, polyvinyl pyrrol i done, ficoll, alginic acid, polypropyleneglycol, and non-toxic polymeric detergents. Non-tox1c polymeric detergents are preferred as protective agents 1n the media of this Invention. Further preferred are non- toxic polymeric detergents which are non-ionic. Editions of McCutcheon's Emulsifiers & Detergents (published by the McCutcheon Division of MC Publishing Co., 175 Rock Road, Glenn Rock, NJ, U.S.A.) are examples of a source of finding non-toxic, non-ionic polymeric detergent candidates for protective agents for the media of this invention, which can be tested for non-toxidty and protective abil ity as indicated above. Preferred non-tox1c, non-ionic polymeric detergents are block copoly ers of propylene oxide and ethylene oxide (polyoxypropylene polyoxyetoylene condensates ), preferably Pl uronic polyol s, such as, Pluronic F68, F77, F88 and F108, preferably F68 and F88, more preferably F68. The Pluronic polyol s are commercially avail able from BASF Wyandotte corp. ( 101 Cherry Hill road, P.O. Box 181, Parslppany, NJ 07054, U.S.A. ). The protective agent 1s preferably present in toe media of this Invention at a concentration which is most effective 1n protecting the Insect cells from damage, but which concentration 1s non-inhibitory to cell growth and reproduction. The Pl uronic polyol polymeric protectants are present in the media of this invention preferably at a concentration (weight-volume ) of from about .01% to about 1%, more preferably from about .05% to about 0.5%, and most preferably about 0.1%. It is further preferred that toe protective agent, preferably a polymeric protectant, also act as an emul sifier of the Hpid component of the media of this invention. Pluronic polyol s, preferably Pluronic F68 or F88, and more preferably Pluronic F68 are protective agent/emu! si fiers of the media of tois invention which can act in conjunction with emulsifier( s ) al ready present in the l ipid/organic sol vent sol ution making up toe l ipid component of the media of this invention as described below. However, the protective agent of the media of this invention need not be an emul sifier to be Included within toe definition herein of a protective agent. If the protective agent is not al so functioning as an emul sifier, the media of tois Invention further comprise another emul sifier that acts to emul sify toe Hp1d component In conjunction with another emulsifier present at a small concentration 1n toe Hpid component Itsel f as described below. Such an emul sifier al ternative to a protective agent/emu! si ffer Is preferably a detergent, preferably non-ion1c which 1s non-tox1c to toe insect cell cul ture at the concentrations required for emul si fication of the l ipid component. The Introduction of the Hpid component in toe form of a icroe ulsion enhances the availability of lipids in the media to the cells. One option for emulsifying the Hpid component is a dual emulsifier system wherein, as noted above, the protective agent 1s an emulsifier as well as a protective agent and can act in conjunction with an emulsifier or combination of emulsifiers present in the Hp1d/organ1c solvent solution making up the Hpid component of the media of this Invention. Another option for emulsifying the Hpid component of the media of this Invention 1s a system wherein the protective agent is not significantly emulsifying but wherein one or more additional emulsifiers are present in an aqueous solution which 1s added to the Hpid component organic solution and act 1n conjunction with the emulsifiers present therein to form a microemulsion. Testing whether an emulsifier, a protective agent/ emulsifier, combination of emulsifiers, or a combination of a protective agent/ emulsifier and an emulsifier or emulsifiers 1s effective in emulsifying the Hpid component can be simply performed as follows. First, the candidate emulsifier or combination of emulsifiers must be confirmed as non-toxic to the insect cells of choice in a manner as described above. Secondly, toe emulsifying ability of the candidate emulslfier(s) 1s tested at the determined non-toxic concentrations. The lipids are dissolved in an appropriate organic solvent, preferably an alcohol (C 1 -C 3 ), more preferably ethanol. The candidate e ulslfer or each of the combination of emulsifiers is then combined with the Hpid/organic solution or in a separate aqueous solution, depending upon in which solution, that is, the organic or aqueous, the candidate emulsifier 1s more readily comblnable. Then the aqueous solution Is added to the 11p1d/organ1c solution and vigorously agitated as by vortexing. Upon agitation, a clear to slightly translucent microemulsion should form If toe Hpid component is successfully emulsified. Preferred emulsifiers added to the l ipid component of the media of this Invention Include phosphol ipids, preferably lecithin and non-toxic non-Ionic polymeric detergents, preferably a polysorbate compound having the formula: wherein R Is a saturated or unsaturated fatty acid having from 16 to 20 carbons, incl usively; wherein t Is an integer between 10 and 30, incl usively; and wherein u is an integer between 10 and 20, incl usively. Most preferably toe non-toxic, non-ionic, polymeric detergent/emu! si fler is polyoxyetoylene (20 ) sorbitan onool eate, otherwise known as polysorbate 80. Such a non-toxic, non-ionic polymeric detergent is commercially avail abl e as Tween 80 from ICI Americas Inc. (New Murphy Road & Concord Pike, Wilmington, DE 19897, USA). Another polysorbate 80 is commercially avail able as Durfax 80 from Durkee Industrial Foods Group/SCM Corp. (900 Union Commerce Bl dg. , Clevel and, Ohio 44115, USA). Other non-toxic, non-ionic, polymeric detergent candidate emul sifiers can be found in edi tions of McCutcheon' s Emul sifiers and Detergents, supra. Said non-ionic, non-toxic, polymeric detergent/ emul sifier, such as, polysorbate 80, 1s present 1n the media of this Invention at a concentration from about 5 mg/1 to about 75 mg/1 , more preferably from about 20 mg/1 to about 30 mg/1 , and most preferably about 25 mg/1 . A preferred example of a dual emul sifier system of the media of this Invention 1s the combination of a protective agent/emul sifler, preferably a Pl uronic polyol , more preferably Pluronic F68 or Pluronic F88, and still more preferably Pl uronic F68, and a non-toxic, non- 1on1c polymeric detergent, preferably a polysorbate compound, and more preferably polysorbate 80. In addition to an emul sifier or emul sifiers, the l ipid component of the media of this fnventfon comprise l ipids essential for toe growth of cell s. Such Hplds are preferably selected from the group comprising fatty adds, steroids and Hpid soluble vitamins. Preferably, such fatty adds are fatty add esters, more preferably polyunsaturated fatty add esters, and still more preferably polyunsaturated fatty add methyl esters. A preferred mixture of polyunsaturated fatty acid methyl esters for the media of this invention 1s fish l iver oil , preferably cod ' iver oil which further contains vitamin A. Preferably, toe steroids are sterol s, and more preferably cholesterol . Preferably toe Hpid sol uble vitamins comprise vitamin E ( al pha- tocopherol ) as well as vi tamin A. Further, the Hpid component of toe media of this ..Invention comprise an organic sol vent, preferably an alcohol , preferably containing from one to three carbons, and more preferably ethanol . A mixture of polyunsaturated fatty acid methyl esters, such as, fi sh l iver oil , preferably cod l iver oil , 1s preferably present in the media at a concentration of from about 1 mg/1 to about 50 mg/1 , preferably from about 5 mg/1 to about 15 mg/1 , and most preferably about 10 mg/1 . Said concentrations of cod l iver oil further contain the preferred concentrations of the Hpid soluble vitamin A. The sterol , preferably cholesterol , 1s at a concentration from about 2 mg/1 to about 7 mg/1 , more preferably from about 3 mg/1 to about 5 mg/1 , and most preferably about 4.5 mg/1. The alcohol , preferably ethanol , 1s at a concentration from about 0.5 ml /1 to about 5 ml/1 , more preferably about 1 ml /1 . The alpha- tocopherol of toe Hpid component 1s at a concentration of from about .5 mg/1 to about 4 mg/1 , more preferably about 2 mg/1. The Hpid component 1s preferably added to toe bul k of the media of the Invention as a microemul sion. An advantage of the Hpid component being 1n the form of a microemul sion, 1n addition to enhancing the avail abil ity of the l ipids to the insect cel l s, 1s in providing toe option of not having to fil ter steril ize toe Hpid component and the rest of the media components separately. The Hpid component 1n the form of a microemulsion can be added to the media without being filter sterilized, and toe entire media can then be filter sterilized without toe concern that lipids, for example, 1n globular form, could be lost during the filter sterilization process. For large scale production, such an advantage is significant. The Hpid component of the media of tois Invention is prepared by combining the appropriate amount of the mixture of lipids, preferably a mixture of polyunsaturated fatty adds, alpha- tocopherol and cholesterol, and toe emuls1f1er(s), 1n an appropriate amount of toe organic solvent, preferably a C1-C3 alcohol to form a solution. At tois point, an aqueous solution containing an emulsifier (or protective agent/emulsifier), which solution is approximately ten-fold greater in volume than the lipid component solution, optionally filter sterilized, can be slowly and, optionally aseptically, added to toe Hpid component solution with agitation as by vortexing. The Hpid component microemulsion is thereby formed. It is the Hpid microemulsion which is added to the media. As another option, the Hpid component can then be easily filtered and sterilized, or the entire medium can be filter sterilized after all additions are compl eted . An exemplary Hpid component of the media of this invention comprises per liter of media: 10 mg cod liver oil 25 mg Tween 80 4.5 mg cholesterol 2 mg alpha-tocopherol 1 ml ethanol. To toe optionally filtered/sterilized Hpid component solution (1 ml), then, 1n this exemplification, 10 ml of 10% Pluronic F68 in water (optionally filtered/sterilized) is slowly added with agitation as by vortexing. The peptone component of the serum- free media of this Invention can be selected from a wide variety of hydrolyzed protein products, either alone or 1n combination, Including, without l imitation, ox ~ i^r digest, such as P nmede (commercially available from Palnes 4 Byrnes Ltd. , Greenford, England), yeast extract, such as Yeastolate (preferably TC Yeastolate from D1fco, USA), caseine digest, such as Bactocasltone (commercially available from Difco, USA), tryptose phosphate broth (TPB) wherein tryptose 1s toe peptone, Lactalbumln Hydrolyzate (LH) (commercially available from Difco, USA) gelatin peptone, glycerin-gelatine peptone, and beef peptone among many other proteolytlc digest products of proteins. Preferably toe peptone component Is composed of peptone fractions either alone or in combination selected from toe group comprising TPB, caseine digest preferably Bactocasltone, ox l iver digest, preferably Panmede, yeast extract, preferably Yeastolate, and Lactalbu in Hydrolyzate (LH). More preferably, the peptone component comprises either LH or Yeastolate, alone or in combination. Still more preferably, the peptone component comprises either a combination of LH and Yeastolate or Yeastolate alone. The total peptone concentration present in the media of tois Invention can be as high as the sum of the highest concentrations of the Individual peptone fractions wherein said highest concentration for each peptone fraction 1s that which is non- toxic and noninhibitory to cell growth and wherein toe total peptone concentration of said highest, non-toxic, noninhibitory concentrations of toe - peptone fractions 1s similarly non-toxic and noninhibitory to cell growth. The highest peptone concentrations can vary not only with the particular peptone fractions, used but also with the particular Insect cell line that Is selected. In general , preferred total peptone concentration present in toe media of this Invention can range from about 1 g/1 to about 12 g/1 , more preferably from about 2 g/1 to about 8 g/1 , and still more preferably from about 3 g/1 to about 5 g/1. One example of a possible peptone component of the media of this Invention employed for Spodoptera fruglperda, cell line Sf9, can be exemplified by a combination of TPB (from about 0 g/1 to about 5 g/1, preferably about 2.5 g/1), Bactocasitone and Panmede wherein the latter two peptones are each at a concentration of about 0 g/1 to about 5 g/1, preferably each at a concentration of about 1 g/1 , a yeast extract, preferably Yeastolate at a concentration of from about 1 g/1 to about 6 g/1, preferably from about 2 g/1 to about 5 g/1, and LH at a concentration from about 0 g/1 to about 6 g/1, preferably from about 1 g/1 to about 4 g/1. Preferably, TPB 1s absent from said peptone component. More preferably, TPB, toe caseine digest (Bactocasltone) and the ox liver digest (Panmede) are also absent from toe peptone component, and the yeast extract, preferably Yeastolate alone at a concentration of from about 2 g/1 to about 5 g/1, more preferably about 4 g/1, or a combination of Yeastolate and LH, each at concentrations from about .5 g/1 to about 4 g/1 wherein the total peptone concentration 1s from about 3 g/1 to about 5 g/1, preferably about 4 g/1, and more preferably where Yeastolate and LH are each at concentrations of about 2 g/1, are the peptone components. Another preferred exemplary peptone component of the serum- free media of tois invention comprises Yeastolate and LH, each at a concentration from about 0.5 g/1 to about 6 g/1, preferably from about 1 g/1 to about 4 g/1 , and more preferably each at a concentration of about 2 g/1. As indicated above, the proportions of Yeastolate and LH are balanced such toat toe total peptone concentration of the .media is within the stated range, and most preferably about 4 g/1. Preferably, the peptones making up the peptone component of the serum-free media of this Invention are prepurffied by ultrafiltration to remove (1) any residual proteases used during toe production of the peptone product; (2) any endotoxins; and (3) any high molecular weight components that could Interfere with purification of any recombinant products expressed by the host Insect cells once Infected with a recombinant baculovirus or viral products produced by insect cells Infected with wild-type viruses. Residual proteases could degrade recombinant proteins or viral products (for example by degrading the protein coat of viral particles ) produced by the Insect cell s, and, therefore, ul trafHtratlon of the peptone fractions 1s considered a preferred mode of preparing the media of this Invention. The peptone fractlon(s ' ) 1s (or Λre) first preferably pre filtered and toen ultra filtered torough a membrane with a molecular weight cutoff selected to be smaller than toe molecular weight of the recombinant or viral product to facil itate later purification, preferably a 2-15,000 molecul ar weight cutoff membrane, more preferably torough a 2-10,000 molecular weight cutoff membrane, and still more preferably through a 10,000 molecul ar weight cutoff membrane such as a PM10 membrane (Ami con ). Said ul tra fil tration process 1s preferably carried out In a cross-flow fil tration apparatus, for example, 1n a pressurized stirred cell for smal l scale or In a hollow fiber cartridge or plate and frame device for large- scale. The ul trafil trate Is toen optionally fil ter steril ized before addition to the basal medium to which the other components of the media of this Invention are al so added. A preferred peptone component of the serum- free media of this Invention 1s prepared as follows: A 10% stock solution of TC Yeastolate (Difco ) Is prefHtered torough a 0.45 micron fil ter. The fil trate Is then ul trafil tered torough a 10,000 molecular weight cutoff membrane (Amlcon PM10 ). The ul trafil trate is then fil ter steril ized, and 20 ml thereof 1s added to 1 Hter of toe basal medium to which the Hpid emul sion described above has al ready preferably been added. A 10% stock sol ution of LH 1s prefH tered, ul trafil tered, and toen fil ter steril ized as directed for toe Yeastolate fraction, and simil arly 20 ml thereof is added to toe medium. The serum-free media of this Invention can contain optional extra water soluble Ingredients, such as, α-glycerol phosphate (at a concentration from about 0.25 g/1 to about 4 g/1 , preferably from about 0.5 g/1 to about 2 g/1 , and more preferably about 1 g/1 ) , glycerol (at a concentration from about 0.5 g/1 to about 5 g/1 , preferably from about 1 g/1 to about 3 g/1 , and more preferably about 2 g/1 ), fol lc add (at a concentration from about 1 mg/1 to about 7 mg/1 , preferably from about 2 rag/1 to about 5 mg/1 , and more preferably about 3.5 mg/1 ), and inosltol (at a concentration from about 2 mg/1 to about 20 mg/1 , preferably about 5 mg/1 to about 15 mg/1 , and more preferably about 10 mg/1 ). Further, toe optional extra water soluble ingredients can comprise antl-peroxi dative enzymes, such as, catal ase, at a concentration of from about 0.5 mg/1 to about 10 mg/1 , preferably from about 1 mg/1 to about 5 mg/1 , and more preferably about 3 mg/1. However, as Indicated In Example 6, below, the effect of el iminating such extra water soluble ingredients from toe media of this Invention was studied In an effort to simplify the medium and to remove any potential inhibitors of cell growth. Prel iminary studies indicated that deletion of toe most expensive of the extra water soluble Ingredients, alpha-glycerol phosphate woul d be beneficial to cel l growth. Further studies wherein al l the extra water sol ubl e Ingredients were el iminated from the medium indicated that the length of the lag phase was reduced and toe specific growth rate was Increased. Therefore, the preferred serum-free media of this Invention do not contain such extra water sol uble ingredients. Insect cel ls which can be grown successfully in the serum- free media of this invention and can produce viral products or recombinant proteins upon infection, respectively, with either wil d- type viruses or recombinant bacuioviruses, are those which have been shown to grow, reproduce and express recombinant and/or viral products in a medium containing serum. Thus, insect cell s toat can be grown in serum containing media can be grown in toe media of this Invention wherein toe serum of the conventional media is replaced with the Hpid component, peptone component, which 1s preferably ul trafiltered, and optionally, but preferably wherein the cul ture is to be well -aerated, with a protective agent as described herein. Further, Insect cell s toat can be grown in IPL-41 basal medium containing approximately 10% serum, can be grown 1n toe serum- free media of this Invention. For example, Insect cell lines from Bo byx mori , Lymantria dispar, Trichoplusla ni and Spodoptera fruglperda are a few of the insect cell s toat have been grown successful ly in basal media, such as IPL-41, containing approximately 10% serum. [See generally, Granados et al . (eds.), The Biology of Bacuioviruses (CRC Press 1986); Vaughn, Adv. Cell. Cult., 1:281 (1981); Vaughn, J. Invert. Pathol., 28:233 (1976); Vaughn, _In_ Maramorosch (ed.), Invert. Tissue Culture: Research Applies., p. 295 (1976); and Vaughn, _lτ^, Bar1gozz1 (eds.) Proceedings of Internatl ♦ Colloq. Invert. Tissue Culture, (2nd, Tremezzo, 1967), p. 119 (1968).] Further, such Insect cells toat can be grown in toe media of this Invention can be from any order of the Class Insecta which can be hosts to a baculovirus expression vector system, or other wild- type viruses, but are preferably from toe Dlptera or Lepidoptera orders. About 300 Insect species have been reported to have nuclear polyhedrosis virus (NPV) diseases, toe majority (243) of which were isolated from Lepidoptera. [Weiss et al., "Cell Culture Methods for Large-Scale Propagation of Bacuioviruses," Jn^ Granados et al . (eds.), The Biology of Bacuioviruses: Vol. II Practical Application for Insect Control, pp. 63-87 at p. 64 (1986).] Insect cell lines derived from the following Insects are exemplary: Carpocapsa pomonella (preferably cell line CP-128); Trichoplusia _ni_ (preferably cell line TN-368); Autographa californica; Spodoptera fruglperda (preferably cell line Sf9); Lymantria dispar; Mamestra brassicae; Aedes albopictus; Orgy i a pseudotsugata; Neodiprion sertifer; Aedes aegypti ; Antheraea eucalypti; Gnorimoschema opercullela; Galleria mellonena; Spodoptera Httolaris; Blatella ger anica; Drosophila melanogaster; Hello this zea; Spodoptera exigua; Rachiplusia ou; Plodia interpunctella; Amsaeta moorei ; Agrotis c-n1grum, Adoxophyes orana, Agroti s segetum, Bombyx mori, Hyponomeuta malinellus, Colias eury theme, Anticarsia germmetalia, Ap an teles melanoscelus, Aretia caja, and Porthetria dispar. Preferred insect cell lines are from Spodoptera fruglperda, and especially preferred Is cell Hne Sf9. The Sf9 cell Hne used in the examples herein was obtained from Max D. Summers (Texas A 4 M University, College Station, TX 77843 USA). Other S. fruglperda cell Hnes, such as IPL-Sf-21AE III, are described 1n Vaughn et al., In Vitro, 13:213-217 (1977). The insect cell lines of this invention are suitable for the reproduction of numerous Insect-pathogenic viruses such as parvovi ruses, pox viruses, bacuioviruses and rhabdovi ruses, of which nucleopolyhedrosis viruses (NPV ) and granulosis viruses (GV ) from the group of bacuioviruses are preferred. Further preferred are NPV viruses such as those from Autographa spp. , Spodoptera spp. , Trichoplusia spp. , Rachlplusia spp. , Gal leria spp. and Lymantria spp. More preferred are baculovirus strains Autographa caHfornica NPV (AcNPV), Rachlplusia ou_ NPV, Gal eria mellonella NPV and any plaque-purified strains of AcNPV, such as E2, R9, SI, M3, characterized and described by Smith et al ., J. Virol . , 30:828-838 (1979 ); Smith et a! . , J. Virol . , 33 311-319 (1980 ); and Smith et al . , Virol . , 89 :517-527 (1978 ). European patent application 127,839 (published December 12, 1984) to Smito et al. describes a method for producing a recombinant baculovirus expression vector, capable of expressing a selected gene in a host Insect cell. Said European application is herein incorporated by reference. The recombinant baculovirus expression vector is cotransfected with wild-type baculovirus DNA into a host insect cell, wherein recombination occurs. Recombinant bacuioviruses are then detected and isolated according to methods described in EP 127,839 and Summers et al., "A Manual and Methods for Baculovirus Vectors and Insect Cell Culture Procedures" supra. The resultant recombinant baculovirus 1s then used to Infect cultured insect cells and the protein product from the incorporated selected gene is expressed by the Insect cells and secreted into the medium. Exemplified therein is toe production of recombinant β-interferon, inter!euk1n-2, and chloramphenicol acetyltransferase (CAT) via toe culturing of ^_ fruglperda cells Infected with a recombinant AcNPV expression vector Into toe genome of which toe appropriate gene had been Inserted. Further Information concerning such a recombinant baculovirus, expression system and Its use In expressing recombinant proteins can be found 1n Summers et al., id.. EP Publication No. 127,839 provides enablement concerning metoods for producing recombinant baculovirus transfer vectors, and recombinant bacuioviruses and for the use of toe recombinant baculovirus expression system for expressing recombinant proteins in host Insect cell s. According to the examples of this Invention, recombinant CSF-1 1s produced by toe host Insect cells cul tured according to this invention. However, those skil led in the art who have the benefit of this disclosure, as well as the above appl ications Incorporated by reference, will recognize toat many other recombinant proteins can be produced by Insect cells infected with recombinant baculovirus according to this invention. Other heterologous proteins that have been expressed In Insect cells via toe BEVS are outlined 1n Summers et al . , Banbury Report: Genetically Altered Viruses In toe Environment, 22 :319-329 (1985 ). Exempl ary recombinant proteins Include, without l imitation those described In copending, commonly owned appl ications (Cetus Docket Nos. 2347, 2382 and 2883 ) colony stimulating factors [for example, long and short form CSF-1 or M-CSF (described below), G-CSF, GM-CSF and interleukin-3 among others] , modified pro-urokinase or urokinase, tissue plasminogen activator (TPA), TPA-urokinase hybrids, toxic proteins such as whole riein toxin, ricin A chain, products containing ricin A, as well as, interferons (a, s and γ and hybrids thereof ), inter! eukins, tumor necrosis factor, erythropoletin and other he atopoietic growth factors, human growth hormone, as well as pordne, bovine and other growth hormones, epidermal growth factor, insulin, hepatitis B vaccine, superoxide di smutase, Factor VIII , Factor VIII C, atria! natriuretlc factor, fel ine leukemia virus vaccines, as, for example, gp70 polypeptides, lectins such as Ridn communis aggl utinin (RCA), diptoeria toxin, gelonin, exotoxin from Pseudomonas aeruginosa, toxic proteins from Phytol acca americana (PAPI , PAPII and • PAP-S ), Insecticidal proteins from Bacill us thuringiensis, many enzymes as for example, CAT, as well as Innumerable other hybrid proteins. "Colony stimul ating factor (CSF-1 )" refers to a protein which exhibits the spectrum of activity understood 1n toe art for CSF- 1, toat 1s, when appl ied to the standard 1n vitro colony stimulating assay of Metcal f, J. Cell Physlol . , 1 89 (1970 ), 1t resul ts 1n the formation of primarily macrophage colonies. Native CSF-1 1s a glycosylated dimer; dlmerizatlon may be necessary for activity. The term CSF-1 herein refers to both dimerlc and monomeric forms. Human CSF-1 Is operative both on human and murine bone marrow cells, whereas murine CSF-1 does not show activity with human cells. Therefore, human CSF-1 should be positive 1n the specific murine radioreceptor assay of Das et al., Blood, 58_:630 (1981). The biological activity of the protein 1s also Inhibited by neutralizing an ti serum to human urinary CSF-1. Das et al. t 1d. CSF-1 1s able to stimulate toe secretion of series E prostaglandlns, lnterleukln-1 and Interferon from mature macrophages. Moore et al., Science, 223:178 (1984). However, toe protein's ability to stimulate toe formation of monocyte/macrophage colonies using bone marrow cells (bone marrow assay) and Its susceptibility to Inhibition by neutralizing antiserum against purified human urinary CSF-1 as well as a positive response to the radioreceptor assay (RRA) or a conventional radioi munoassay (RIA) can be employed to Identify CSF-1 produced by Insect cells via a recombinant baculovirus expression vector system (BEYS). The Insect cells grown 1n the serum-free media of tois Invention are cultured In a temperature range and under conditions appropriate for toe particular cell Hne selected. For example, Spodoptera frugiperda cell s, preferably Sf9 cell s, are cultured in a temperature range of from about 25 β C to about 32 β C, preferably from about 27 β C to about 28 β C and wherein the pH of the cul ture medium is preferably maintained in a range of from about 6 to about 7, more preferably about 6.2 to about 6.4. The effect of timing of the infection of toe insect cell s wi th a recombinant baculovirus has been shown to be critical for enhanced specific productivity. The speci fic production of the recombinant protein was found to be constant during the exponential phase of cell growth under non-oxygen l imited conditions. Late infection, under non-exponential growth conditions, resul ted in lower specific productivity and lower final titer. It is preferred that toe exponential growth phase be extended to the highest possible cell densities to achieve toe highest total productivity of the recombinant protein product. Infection of the host insect cell s under conditions toat l imit growto, for example, in the stationary phase of cell growth, results 1n a reduced specific productivity of the recombinant protein product. Specific productivity of toe recombinant protein product is rel atively Independent of cell density at the time of Infection as long as toe culture 1s 1n exponential growto. For example, when Spodoptera frugiperda cells are toe host insect cells and the media of this invention are used, preferred cell densities of from about 1.0 x The timing of the harvest of the recombinant protein product 1s critical to avoid contamination of the recombinant protein by viral and cell lysis proteins and to simplify thereby the downstream purification of the recombinant product. With considerations for the stability of toe product, It would be preferred to harvest the recombinant product before significant cell lysis has occurred. Further, each recombinant protein or viral product to be produced according to toe methods and media of this Invention should be checked for stability and degradation over the course of toe fermentation run. Such considerations should enter into a determination of the optimal harvest time. The following examples further Illustrate the serum- free media of this Invention, the growth of Insect cells under non-oxygen limited conditions in such media and the production of recombinant protein products by such insect cells via a recombinant baculovirus expression vector system. These examples are not Intended to limit the Invention in any manner. EXAMPLE 1 Development of a Serum-Free Growth Medium This example outlines the development of a serum- free medium for the growth of insect cells. Results of growing Spodoptera frugiperda cells (Sf9) 1n a serum containing media, were compared with toe growto of Insect cells 1n two candidate serum- free media. The control medium was IPL-41 complete medium as described 1n Weiss et al., In Vitro, 7J6):495-502 (June 1981) which 1s prepared by adding 2% (v/v) tryptose phosphate broth (TPB) and 10% (v/v) fetal bovine serum (FBS) to IPL-41 basal medium. Said complex control medium contains serum and protein hydrolysates at a total protein concentration of approximately 7 g/L. _ _ Candidate serum-free medium #1 (SFM #1) was prepared by adding to IPL-41 basal medium, that 1s, IPL-41 complete medium wherein the TPB and FBS are omitted, the following supplements: Tryptose phosphate broth 2.6 g/1 Bovine Serum Albumin (fatty add free) 1.0 g/1 Glycerol 2.0 g/1 Pluronic Polyol (F68) 1.0 g/1 Alpha-Glycerol Phosphate 1.0 g/1 FoHc Add 3.6 mg/1 Cod Liver 011 10.0 mg/1 Tween 80 25.0 mg/1 Cholesterol 4.5 mg/1 α-tocopherol acetate 2.0 mg/1. Candidate serum- free medium #2 (SFM #2) was similarly prepared by adding to IPL-41 basal medium the following supplements: The Sf9 cells 1n SFM #1 at passages 1, 2 and 3 grew at a rate and to a final cell density significantly reduced as compared to toe cells 1n the serum-containing control media. Continued passage 1n the medium resulted 1n further decrease in growth. The culture of Sf9 cells in SFM #2 at passage 1 went torough a long lag phase followed by growto to densities typical for Sf9 cells grown in the 10% serum containing medium. At passage 2, toe cells had adapted to toe SFM #2 and did not demonstrate the long lag phase. The growto rate and final cell density again approximated those of cultures containing 10% FBS. SFM #2 was shown to support the growth of Sf9 cells for over seven passages. EXAMPLE 2 Modified SFM #2 Supports Sf9 Growth and Expression of CSF-1 This example demonstrates that a modified version of SFM #2 of Example 1 supports both the growto of the S. frugiperda cells and their production of recombinant CSF-1 (short form) when the Sf9 cells are infected with a recombinant baculovirus AcM4 which has Inserted within Its genome a cDNA sequence encoding for a biologically active colony stimulating factor . 1 (CSF-1) protein. Both the modified SFM #2 culture and 10% serum containing control culture of the Sf9 cells infected by the recombinant baculovirus produced approximately 300,000 U/ml of the recombinant CSF-1. 50 ml cultures of Sf9 cells were grown in 250 ml shake flasks agitated at 150 RPM with an orbital radius of gyration of one- half Inch at 27 β C. Total cell counts were determined with a Coulter Counter and viability of toe cells was checked by trypan blue exclusion. The cells were maintained 1n either IPL-41 complete medium as described above with 2% TPB and 10% heat Inactivated FBS plus 0.1% Pluronic polyol (F68) or In modified SFM #2 (SFM2M) as described Immediately below. The SFM #2 of Exampl e 1 contains 1 g/1 of bovine serum albumin (BSA). The other major substitute therein for serum 1s a combination of three peptones, each suppl ied at 1 g/1 as fol lows : yeast extract, Bactocasltone and Panmede. Modification of the peptone 5 content of SFM #2 was investigated to simpl ify downstream purification of the recombinant protein product. In addition to toe 3 g/1 of peptones, the SFM #2 further contains 2.6 g/1 tryptose phosphate broth (2 g/1 tryptose as does toe IPL-41 complete medium). It was found by reducing the peptone concentration to 1.5 g/1 , 0.6 g/1 , 0.3 g/1 and to 10 0 g/1 respectively, whereas the TPB concentration was maintained at 2.6 g/1 , and by comparing toe growto curves to those of cultures grown at 3 g/1 of peptones, that the peptone concentration was critical . The 3 g/1 peptone cul ture of SFM #2 resul ted in a satisfactory cel l growto rate, that is, a popul ation doubl ing time (Td) of 24 hours as 15 compared to 17 hours for a typical 10% serum containing cul ture, and maximum cell densities of 4-5 x IO 6 cell s/ml which were equivalent to 10% serum containing cul tures. However, when toe peptone concentration was reduced from 3 g/1 to 0 g/1 , the maximum cell density attained was significantly reduced. 20 The peptones were ul trafil tered to remove (1 ) any high molecular weight components toat might Interfere with product puri fication; (2 ) potentially residual proteases from the peptone production process; and (3 ) endotoxins. The peptones, but not the TPB, were ul trafil tered with a pressurized stirred cell through a 25 10,000 molecul ar weight cut-off membrane (Amicon PMIO ) before being added to the serum-free medium. Growth of the Sf9 cel l s on the serum- free medium containing the peptone fil trate was found to be equivalent to toat with toe whole peptone. The peptone ul trafil trate retentate was dlafil tered 20x with water; 1t was shown not to enhance growto of 30 the Sf9 cells significantly as compared to serum- free cul ture wherein no additional peptone was added. It was determined that toe TPB presented problems 1n toe purification of the recombinant CSF-1. Therefore, TPB was ul trafil tered as described above for the three peptones torough a PMIO 35 membrane prior to addition to the serum-free medium. The combination . -33- of the PMIO fil trates of both toe TPB and three peptones resul ted 1n growth of Sf9 to a maximum cell density similar to the 10% serum containing media and to toe unfil tered SFM #2. Thus, a new serum-free medium version designated SFM2M contains al l peptones Including TPB pre-ultrafil tered. Growth 1n toe 10% serum medium was faster than In SFM2M. The metoods of preparing recombinant baculovirus AcM4 by cotransfecting Insect cells wito pAcM4 and wild-type baculovirus DNA and then detecting and purifying the recombinant baculovirus were carried out essentially as described in said U.S. patent appl ication. [See al so, European Patent Appl ication No. 127,839 and Summers et al . , "A Manual of Methods for Baculovirus Vectors and Insect Cel l Cul ture Procedures" , supra.] Infection with the recombinant baculovirus was performed at a rel atively low cell density (1-1.5 x 10° cell s/ml ) with a mul tipl icity of infection (MOD of 2. Both the SFM2M and 10% serum containing control cul ture produced 300,000 U/ml of the recombinant CSF-1. The CSF-1 level s were estimated by RIA. Most of the CSF-1 was produced within 48 hours after infection with toe recombinant baculovirus, and before the cell s had lysed. To avoid contamination of the cul ture supernatant by cell lysis, it 1s desirable to time the harvest of toe recombinant protein product harvest prior to cell lysis. It was determined that IO 6 U of recombinant CSF-l/ml could be produced by Sf9 cell s Infected with the recombinant baculovirus AcM4 in SFM2M during toe exponential growto phase. The specific production (U/cell ) of the recombinant CSF-1 appeared to pe constant during toe exponential phase of growto, under non-oxyge l imited conditions. Infection with AcM4 at a cell density of 2.? x IO 6 cell s/ml produced 1.2 x IO 6 U of rCSF-1/ml by RIA and 2.5 x IO 6 U rCSF-1/ml as estimated by toe bone marrow bibassay. [The bone marrow proliferation assays are performed according to Moore et al., J. Immunol . , 131:2374 (1983) and Prystowsky et al., Am. J. Pathol., 114:149 11984).] Little change was noted in the (short clone) rCSF-1 by Western analysis of samples from day 1 torough day 4 post- Infection. Late Infection, under non-exponential growto conditions, resulted In a lower specific productivity and lower final titer. It was therefore concluded that Infection at higher cell density (but still In toe exponential growto phase) would increase rCSF-1 production. EXAMPLE 3 Elimination of BSA from SFM2M This example shows that the growto of Sf9 cells 1n SFM2M containing 1 g/1 of bovine serum albumin (BSA) was similar to that found in SFM2M without any BSA. Likewise, the production of rCSF-1 in such an essentially protein-free medium (SFM2M without BSA) was equivalent to that seen in SFM2M wito BSA. 50 ml cultures of Sf9 cells were grown 1n 250 ml shake flasks agitated at 100-150 rpm (with an orbital radius of one-half inch) at 27 β C, in both SFM2M and SFM2M without BSA. The recombinant baculovirus AcM4 was used to infect exponentially growing cultures at a MOI of 1. Little or no effect on growth rate or maximum cell density was observed in the cultures without BSA versus those with BSA. A number of other SFM2M with no BSA cultures of Sf9 cells have been grown in shake flasks and infected wito AcM4. Culture volumes of 25-250 ml 1n 125-1,000 ml flasks have repeatedly produced IO 6 U rCSF-1/ml, by 4 or 5 days after Infection. Immunoprecipitation, followed by SDS-PAGE, as well as Western analysis, indicated that toe rCSF-1 (short clone) is not degraded 1n the culture broth of this essentially protein-free medium, that is, SFM2M with no BSA. The SFM2M with no BSA stil l contains 3 mg/1 catal ase and 5 g/1 mixed peptones of molecular weight lower than 10,000. The composi tion of SFM2M with no BSA is as fol lows : IPL- 1 Basal Medium Ultrafiltered Peptones Tryptose Phosphate Broth Bactocasltone (caseine digest) Panmede (ox l iver digest) Yeastolate (yeast extract) Extra Water Soluble Ingredients α-Glycerol phosphate Glycerol FoHc Acid -,,.,, Inositol Catal ase Pluronic polyol -Hpid Emulsion Pl uronic polyol F68 Cod Liver Oil Tween 80 Chol esterol α-Tocopherol acetate EXAMPLE 4 Importance of Physical Protectant It was found toat al though BSA Is not necessary for Sf9 cel l growto or production of toe recombinant protein product that toe el imination of toe Pl uronic polyol (F68 ) from toe medium even 1n the presence of 10% serum resul ts 1n cell deato 1n shake flask cul tures. The Pluronic polyol 1s essential as a physical protectant in shake flasks, and it also serves to emul sify Hpids. EXAMPLE 5 Peptone Modifications of SFM2M without BSA Example 3 outlines the composition of SFM2M witoout BSA. In this example, more simplified media are described wherein toe peptone component of SFM2M witoout BSA 1s modified. The total peptone composition of SFM2M witoout BSA 1s 5 g/1. The growto rate of Sf9 cells 1n such medium was slow wito a doubling time (Td) of 30-45 hours after numerous passages (10-20), whereas toe doubling time (Td) of Sf9 cells tn 10% serum containing medium is from about 17-24 hours. The peptone composition of SFM2M without BSA was modified to obtain a faster growth rate and thereby more efficient production of recombinant proteins from Sf9 cells infected with a recombinant baculovirus. Also, a redaction in the number of peptones simplifies media preparation and downstream purification of the recombinant protein product. Peptone modifications of SFM2M without BSA were prepared wherein, to media containing TPB at 2.6 g/1, the following peptone additions were made: (1) 3 g/1 Yeastolate, or (2) 3 g/1 Bactocasltone, or (3) 3 g/1 Panmede. Further, two media were prepared wherein tryptose (as TPB) was the only peptone component at 2 g/1 and 5 g/1, respectively. The media were inoculated with Sf9 cells that had been maintained in SFM2M without BSA for over 15 passages (about 50+ generations). The Sf9 cultures of 50-100 ml in 250 ml shake flasks were agitated at 100-150 rpm at 27°C. Cell density was measured with a Coulter Counter. Typical cell viabilities of exponential phase cultures has been 99- 100% as determined by trypan blue exclusion. The poorest growto was found in toe medium containing only TPB (at both 2 and 5 g/1 tryptose), as toe peptone component. The addition of toe other peptones to the medium enhanced growth significantly. The best growto was found 1n the medium containing TPB plus Yeastolate, al though a long lag phase (two to three days before exponential growth began) was noted. As toe TPB appeared to Inhibit cel l growth, peptone modifications of SFM2M without BSA media were prepared wherein TPB was el iminated. Panmede at 5 g/1 as the only peptone component of modified SFM2M without BSA appeared to Inhibit growth. Bactocasl tone at 5 g/1 as toe only peptone component supported growto to a low cel l density and at a slow exponential growto. The trlpeptone (Yeastol ate, Panmede and Bactocasltone) at 5 g/1 and Yeastol ate only at 5 g/1 cul tures both grew wel l ; however, the Yeastolate cul ture, again, had toe fastest exponential growto rate, but a long lag phase. Experiments with Yeastol ate alone as the peptone component at 2, 4, 6, 8 and 10 g/1 , respectively, indicated that at concentrations of 4 g/1 and above, increasingly longer l ag phases or Inhibition of exponential growth occurred. There was a short lag phase in cul tures containing Yeastol ate at 2 g/1 . Al though the 4 g/1 Yeastol ate cul ture had a long l ag phase, it grew the fastest and achieved sl ightly higher maximum cell densities. To reduce the lag phase of such cul tures containing Yeastol ate as the peptone component of the media, Yeastol ate at a l ow concentration (2 g/1 ) was combined wi th ul trafil tered Lactal bumin Hydrolyzate (LH) at 0, 2 and 4 g/1 , respectively, because LH had been shown by prel iminary studies to support a fast growth rate with no lag phase. The LH apparently reduced the lag phase of the 2 g/1 Yeastolate cul ture and increased toe maximum cell density. However, a 4 g/1 Yeastolate culture without LH demonstrated a relatively short lag phase Indicating toat the Sf9 cell s having been grown for several passages In toe 4 g/1 Yeastolate medium apparently adapted to Its Inhibitory effects. This example thus Indicates toat the peptone composition of SFM2M without BSA coul d be advantageously modi fied to contain Yeastol ate al one at 4 g/1 or Yeastol ate pl us LH (2 g/1 each ) as the peptone component. EXAMPLE 6 Elimination of Water Soluble Ingredients: ISFM-3 and ISFM-4 In parallel with toe peptone modification studies described 1n Example 5, the role of other Ingredients of SFM2M witoout BSA were examined. As shown 1n Example 3, SFM2M without BSA contains the following defined water soluble ingredients: -glycerol phosphate (1 g/1); glycerol (2 g/1); folic add (3.6 g/1); inosltol (10 mg/1); and catalase (3 mg/1). The first four such Ingredients had been added to toe serum- free media because of growto stimulatory effects claimed 1n the literature for another Lepidopteran insect cell Hne. [Goodwin et al., Invertebrate Systems (1980), supra.] Catalase had been added as a protectant from peroxidation damage that was anticipated to occur under the highly aerated conditions used to grow Sf9 cells in shake flasks. It was found toat removal of these water soluble ingredients from the SFM2M medium witoout BSA had beneficial effects on cell growth, reducing the lag phase and increasing toe specific growth rate, while maintaining the maximum cell density. Thus, the serum- free medium was simplified to contain: (1) basal medium (IPL-41); (2) Pluronic polyol -Hpid emulsion; and (3) peptone(s) of choice. SFM2M witoout BSA and without the water soluble ingredients wherein the peptone component comprises 2 g/1 Yeastolate and 2 g/1 LH was designated ISFM-3, and wherein toe peptone component comprises 4 g/1 Yeastolate, such medium was designated ISFM-4. Both toe I SFM- 3 and ISFM-4 cultures grew well but toe ISFM-4 culture was shown to have a longer lag phase. The compositions of ISFM-3 and ISFM-4 therefore are as follows: IPL-41 Basal Medium Ultrafiltered Peptones 4 g/1 Pluronic Polyol -Lipid Emulsion Pluronic Polyol F68 1 g/1 Cod Liver Oil 10 ιβg/1 Tween 80 25 mg/1 Cholesterol .4.5 mg/1 o-Tocopherol Acetate 2 mg/1 wherein toe ultrafiltered peptones comprise 2 g/1 of Lactalbumln Hydrolysate (LH) and 2 g/1 of Yeastolate for ISFM-3; and wherein t e ultrafiltered peptones comprise 4 g/1 of Yeastolate for ISFM-4. To overcome the problem of the ISFM-4 lag phase, a Yeastolate fed-batch culture was tested. An ISFM medium containing 2 g/1 Yeastolate (no other peptones and no extra water soluble ingredients) was used to grow Sf9 cells to 1.2 x IO 6 cells/ml. At that point, an additional 1 g/1 of Yeastolate was added to the culture. The culture was then grown to 2.6 x IO 6 cells/ml, and an additional 2 g/1 of Yeastolate was added. The strategy resulted in a reduced lag phase (15 hours), rapid cell growto (equivalent to 10% serum containing cultures) and increased maximum cell densities in cultures fed wito higher amounts of Yeastolate (up to 6-7 x IO 6 cells/ml). The long lag phase of ISFM-4 culture without the Yeastolate fed batch approach further became less of a problem upon continued passaging of Sf9 in toe medium, probably because of adaptation to the Yeastolate. Cultures grew equally well with short lag phases in ISFM- 3 and ISFM-4 by toe third passage. Table 2 lists toe average growth characteristics of 8 passages in these two media. These media provide growto rates (Td ■ 17-24 hours) and maximum cell densities (5 x IO 6 cells/ml) similar to those found in 10% serum media. TABLE 2 Lag Phase* Population Doubling Maximum Cell Density (hours) Time (hours) (IO 5 cells/ml) ISFM-3 14 22 5.0 ISFM-4 15 22 6.1 * Lag phase was calculated by extrapolating toe exponential phase plot (semi-log) back to the Initial cell density (1 x IO 5 cells/ml). The x-intercept (hours of culture incubation) Is equal to the lag phase. EXAMPLE 7 Production of Recombinant CSF-1 by Insect Cells Grown in Serum-Free Media and Infected with Recombinant Baculovirus AcM4 Sf9 cells grown for 25-30 passages (75-120 generations) in toe serum-free media of tois invention were tested for production of rCSF-1 upon Infection with the recombinant baculovirus AcM4. Table 3 lists such Sf9 cultures infected with AcM4 under similar exponential growto conditions. Such cultures were grown according to the procedures outlined in toe above examples. TABLE 3 rCSF-1 Production by Sf9 Cells Growing in Various Media at 5 Days after Infection with AcM4 * 10% serum is IPL-41 complete medium with TPB and FBS. As shown In Tabl e 3, al l of toe cul tures produced simil ar level s of rCSF-1, at about IO 6 U/ml as estimated by RIA. The production of rCSF-1 was not affected by the slower exponential growth rate afforded by toe SFM2M without BSA medium. EXAMPLE 8 Sf9 Adaptation to SFM2M without BSA, ISFM-3 and ISFM-4 It was found that toe original Sf9 maintained In the 10% serum containing medium (IPL-41 complete medium) readily adapted to SFM2M without BSA, ISFM-3 and ISFM-4 upon the first and second passages. Subsequent passages and infections wi th the recombinant baculovirus AcM4 have verified the resul ts described above and Indicate that SFM2M without BSA, ISFM-3 and ISFM-4 are a suitabl e media for large-scale growth of Insect cell s and for the production of recombinant protein products thereby via a recombinant bacul ovirus expression vector system. EXAMPLE 9 Production of Recombinant CSF-1 by Insect Cell s Grown in ISFM-4 and Infected with Recombinant Baculovirus AcM6 50 ml cul tures of Sf9 insect cel l s were grown in 250 ml shake fl asks agitated at 100-150 rpm (with an orbital radius of one- hal f inch ) at 27 β C, 1n ISFM-4. The recombinant baculovirus AcM6 was used to Infect an exponential ly growing cul ture at an MO I (mul tipl icity of Infection ) of 1. To determine the optional time to harvest the rCSF-1, samples of the cul ture were removed daily after Infection with the recombinant baculovirus, centrlfuged and supernatants Immediately frozen. These sampl es were analyzed for rCSF-1 using Western blotting, RIA and bone marrow assay. Samples containing 600 RIA uni ts of rCSF-1, that had been diafiltered into 0.1 M NaP0 (pH 6.8) and reduced with β-mercaptoethanol , were run on SDS-PAGE for Western analysis. Rabbit anti serum to denatured, monomeric 18K-A rCSF-1 (158 amlno acids) from j _ col l were used as toe primary antibodies for detection of rCSF-1. The blots were developed using goat anti -rabbit IgG followed by lodinatlon with 125 I-protein A to visual ize toe proteins through autoradiography. Figure 1 shows toe time course of: rCSF-1 concentration in cul ture medium (top panel ), Insect cell viabil ity (middle panel ) and Western analysis of rCSF-1 homogeneity * On the day of infection with the rbaculovlrus, only trace levels of secreted rCSF-1 were present by RIA (top panel , day 0). rCSF-1 concentration (by RIA) increased torough day 4 and reached a peak of 8 x IO 5 U/ml . Bone marrow assays confirmed the RIA data. Western blot analysis (lower panel ) of 600 RIA units from each of the daily samples of the culture supernatant shows that rCSF-1 consisted of a triplet band of about 40K and a single band of 70 on days 1 through 3 post-Infection. The relative intensity of the 70K band decreased on day 3. On day 4, a new set of 4 rCSF-1 bands appeared, of apparent sizes 45K, 35 , 25K and 20 . This major change in rCSF-1 by day 4 was correl ated with the rapid death phase of toe infection/production process ( top panel ). Al though the biological activity of the rCSF-1 was retained (as confirmed by the bone marrow assay ), the sizes and heterogeneity of toe protein were changed. This suggests toat the timing of harvest of tois AcM4 rCSF-L can be optimized to obtain the most preferred rCSF-1 product. In contrast to the labil ity of the rCSF-1 produced by Infections of the Insect cell s by AcM6, toe rCSF-1 produced by Insect cell s Infected with AcM4 according to Example 7, above, did not change significantly 1n size or heterogeneity through toe cell deato phase, and up to 5 days after Infection. Conclusion In summary, It can be seen that the serum-free media of this invention provide simpl ified, low-cost media for the large-scale growth of Insect cel l s under agitated and/or sparged, preferably wel l - aerated conditions, and for the production therefrom of recombinant proteins via a recombinant wil d- ype baculovirus expression vector system or other viral products by Infection with viruses. Such media simpl ify toe purification of the recombinant protein and viral products by toeir low or essentially no protein content, l ack of serum, and by ul tra filtration of toe peptone components thereof. Deposit As mentioned above, the recombinant baculovirus transfer vectors pAcM4 and pAcM6 in E. col i/MM294 have been deposited at the American Type Cul ture Collection (ATCC), 12001 Park! awn Drive, Rockvil le, MD 20852 (U.S.A. ) on June 12, 1987 under the respective ATCC Nos. 67429 and 67428. Said deposi ts were made pursuant to a contract between toe ATCC and the assignee of this patent appl ication, Cetus Corporation. The contract with the ATCC provides for permanent avail abil i ty of said strains and progeny thereof to the publ ic upon Issuance of a U.S. patent related to this appl ication describing and identifying the deposits or upon the publ ication or l aying open to the publ ic of any U.S. or foreign patent appl ication, whichever comes first, and for the avail abil ity of the strains and the progeny thereof to one determined by the U.S. Commi ssioner of Patents and Trademarks to be enti tled toereto according to 35 USC $122 and toe Commissioner' s rules pursuant toereto (Including 37 CFR $1.14 with particular reference to 886 OG 638). The assignee of the present appl ication has agreed toat if the strains on deposit should die or be lost or destroyed when cultivated under suitable conditions, they will be promptly replaced upon notification with a viable cul ture of toe same strain. The deposits under the terms of the Budapest Treaty assure that said cul tures deposited will be maintained in a viable and uncontaminated condition for a period of at least five years after the most recent request for toe furnishing of a sample of toe deposited microorganism was received by toe ATCC . and, in any case, for a period of at least 30 years after the date of the deposit. Availabil ity of the deposited strains 1s not to be construed as a l icense to practice the invention In contravention of toe rights granted under toe authority of any government In accordance with its patent laws. Al so, toe present invention Is not to be considered l imited in scope by the deposited recombinant transfer vectors, since the deposited vectors are Intended only to be il l ustrative of particul ar aspects of the invention. Any recombinant baculovirus transfer vector which can be used to prepare recombinant bacuioviruses which can function to Infect a host Insect cell to produce a recombinant protein product is considered to be within the scope of this invention. Further, various modifications of the Invention in addition to those shown and described herein apparent to those skilled In the art from the preceding description are considered to fall within the scope of the appended cl aims.

Claims: WHAT IS CLAIMED IS: 1. A serum free medium which supports the large scale growth of insect cells and the production thereby of recombinant and viral products at levels comparable to those achieved n serum containing media, comprising: (a) a basal medium; (b) a lipid component; and (c) a peptone component 2. A serum free media according to claim 1 further comprising a protective agent. 3. A serum free medium according to claim 1 wherein the recoinbinant product is a colony stimulating factor, an interferon, an interleukin, tumor necrosis factor, erythropoietin, human, porcine or bovine growth hormone, epidermal growth factor, insulin, Factor VIII, modified pro- urokinase, urokinase, tissue plasminogen activator (TPA), a TPA-urokinase hybrid protein, hepatitis B vaccine protein, feline leukemia virus vaccine protein, superoxide dismutase, atrial natriuretic factor, whole ricin toxin, ricin A chain, ricin a hybrid protein, a lectin, diphtheria toxin, gelonin, Pseudomonas aeruginosa exotoxin, PAPI, PAPII, PAP-S, CAT, or a Bacillus thuringiensis toxic protein. 4. A serum free media according to claim 3 wherein the lipid component is in the form of a microemulsion. 5. A serum-free medium according to claim 2 wherein the basal medium is a nutrient mixture of inorganic salts, sugars, amino acids, optionally also containing vitamins, organic acids and/or buffers; 6. A serum free medium according to claim 5 wherein the protective agent is selected from the group comprising hydroxyethyl starch, methyl cellulose, carboxymethyl cellulose, dextran sulfate, polyvinylpyrrolidone, ficoll, alginic acid, polypropyleneglycol and non-toxic polymeric detergents; an emulsifier wherein the protective agent selected does not have emulsifying properties; the emulsifier of the lipid component is a phospholipid and/or a non-toxic, non-ionic polymeric detergent; the organic solvent is an alcohol containing from one to three carbon atoms; the lipids of the lipid component are selected from the group comprising fatty acids, steroids and lipid soluble vitamins; and the peptone component is at a total concentration of from about 1 g 1 to about 12 g 1. 7. A serum free medium according to claim 6 wherein the protective agent is a non-toxic, non-ionic polymeric detergent; the emulsifier of the lipid component is lecithin and/or a polysorbate compound having the formula 0 / \ H,C CH-CE ,-CCOR ' I I • ■ H(C 2 H 4 0) t HOC CHO(C 2 H 4 ) u H CHO(C 2 H 4 ) u H wherein R is a saturated or unsaturated fatty acid having from 16 to 20 carbons, inclusively; wherein t is an integer between 10 and 30, inclusively; u is an integer between 10 and 20, inclusively; the organic solvent is ethanol; the lipids of the lipid component are selected from the group comprising fatty acid esters, sterols, Vitamin A and alpha-tocopherol; and the peptones of the peptone component are selected from the group comprising caseine digest, ox liver digest, yeast extract, tryptose phosphate broth (TPB) and Lactalbumin Hydrolyzate (LH). 8. A serum free medium according to claim 7 wherein the non-toxic, non-ionic polymeric detergent is a block copolymer of propylene oxide and ethylene oxide; the lipids of the lipid component are selected from the group comprising polyunsaturated fatty acid esters, sterols, Vitamin A and alpha- tocopherol; and the peptones of the peptone component are selected from the group comprising PanMeade, TPB, yeast extract, Bactocasitone and Lactalbumin Hydrolyzate (LH). 9. A serum free medium according to claim 8 wherein the non-toxic, non-ionic polymeric detergent is a Pluronic polyol; the emulsifier of the lipid component is lecithin and/or polysorbate 80; the lipids of the lipid component are selected from the group comprising a mixture of polyunsaturated fatty acid methyl esters, sterols, Vitamin A and alpha-tocopherol; and the peptone component is selected from the group comprising TPB at a concentration from about 0 g 1 to about 5 g/1, Bactocasitone and PanMeade wherein the latter two peptones are each at a concentration of about 0 gΛ to about 5 gΛ, and yeast extract at a concentration of from about 1 gΛ to about 6 gΛ, and LH at a concentration from about 0 gΛ to about 6 gΛ. 10. A serum free medium according to claim 9 wherein the basal medium is IPL-41; the Pluronic polyol is selected from the group comprising Pluronic F68, F77, F88 and F108; the lipids of the lipid component are selected from the group comprising fish liver oil, cholesterol and alpha-tocopherol; and the peptones are selected from the group comprising yeast extract and LH. 11. A serum free medium according to claim 10 wherein the Pluronic polyol is selected from the group comprising Pluronic F68 and Pluronic F88; the lipids of the lipid component are selected from the group comprising cod liver oil and cholesterol; and the peptones are selected from the group comprising Yeastolate and LH. 12. A serum free medium according to claim 11 wherein the lipid component comprises cod liver oil at a concentration from about 1 mgΛ to about 50 mgΛ, cholesterol at a concentration from about 2 mgΛ to about 7 mgΛ. ethanol at a concentration from about 0.5 ml/1 to about 5 mlΛ, polysorbate 80 concentration from about 20 mgΛ to about 30 mgΛ, and the alpha-tocopherol at a concentration of from about 0.5 mgΛ to about 4 mgΛ; and the peptone component is at a total concentration of about 3 gΛ to about 5 gΛ. 13. A serum free medium according to claim 11 wherein the Pluronic polyol is Pluronic F68 at a concentration of from about .05% to about 0.5%; and the lipid component comprises cod liver oil at a concentration from about 5 mgΛ to about 15 mgΛ, cholesterol at a concentration from about 3 mgΛ to about 5 mgΛ, ethanol at a concentration of about 1 mlΛ, polysorbate 80 at a concentration of about 25 mgΛ, and alpha-tocopherol at a concentration of about 2 mgΛ. 14. A serum free medium according to claim 13 wherein the Pluronic F68 is at a concentration of about 01%; the cod liver oil is at a concentration of about 10 mgΛ; the cholesterol is at a concentration of about 4.5 mgΛ; and the peptone component comprises Yeastolate at a concentration from about 2 gΛ to about 5 gΛ and LH at a concentration from about 1 gΛ to about 4 gΛ. 15. A serum free medium according to claim 14 wherein the peptone component is ultrafiltered and comprises a combination of Yeastolate and Lactalbumin Hydrolyzate wherein each is a concentration from about 0.5 gΛ to about 4 gΛ. 16. A serum free medium designated ISFM-3 or ISFM-4. 17. In a method which comprises cultivating and reproducing inseςt cells for the production thereby of recombinant and viral products in a nutrient mixture containing inorganic salts, sugars, amino acids, and optionally also containing vitamins and organic acids, the improvement which comprises replacing serum and/or serum albumin with a lipid component and a peptone component. 18. In a method according to claim 17 wherein the improvement further comprises adding a protective agent as replacement for serum and/or serum albumin. 19. In a method according to claim 17 wherein the lipid component is added in the form of a microemulsion.

Inventors: INLOW DUANE, MAIORELLA BRIAN, INLOW, DUANE, MAIORELLA, BRIAN
Applicants: CETUS CORP, CETUS CORPORATION
Application year: 1988
Main classification: C12N5
IPC codes: C07K14, C12N5, C12N15, C12P21, C12R1